MigraineNCT07593287
PEDİATRİC MİGRAİNE PATİENTS İN FİNDİNGS
An observational study of Migraine and Pediatric Migraine, run by Mersin University at 1 site in Turkey (Türkiye).
Trial summary
Migraine is a common neurological disease in the pediatric population. However, studies investigating the clinical symptoms associated with the different phases of migraine attacks (prodrome, aura, postdrome), particularly in childhood and adolescence, remain limited. Read more about this study
- Who is it for?
- Ages 6 to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- Migraine, Pediatric Migraine
- How many people
- 45 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Apr 2021to 1 Dec 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: Pediatric migraine
Who may be able to join
None listed.
Who cannot join
- Primary headaches
- Hemiplegic migraine
- Depression
- Anxiety
Trial locations and contacts
1 site in 1 country.
About this study
Official title: EVALUATİON OF POSTDROME FİNDİNGS İN PEDAİTRİC MİGRAİNE PATİENTS
Migraine is a common neurological disease in the pediatric population. However, studies investigating the clinical symptoms associated with the different phases of migraine attacks (prodrome, aura, postdrome), particularly in childhood and adolescence, remain limited. The aim of this study was to evaluate the clinical symptoms experienced by children with migraine during attack phases (prodrome, aura, postdrome) and to investigate potential differences in these symptoms according to age and gender The first 18 questions assessed sociodemographic variables, including age, sex, body weight, parental characteristics, social status, age at migraine diagnosis and symptoms, knowledge of migraine, family history of migraine, comorbid conditions, and access to healthcare services. The second part of the questionnaire consisted of questions on headache and migraine-related symptoms and clinical characteristics (questions 19-26), migraine treatment (questions 28-34), and postdrome features (questions 35-39). The study examined migraine-related symptoms and clinical characteristics, treatment approaches, and the influence of sex and age group on the stages of migraine.
All patients underwent an assessment of headaches within the last three months, along with physical and neurological examinations. The diagnosis of migraine was made according to the ICHD-III criteria.
Read the detailed description
A migraine attack consists of four main stages. These stages are premonitory, aura, headache and postdrome periods. The prodromal or premonitory phase of migraine is generally defined as the period 2-48 hours before the aura or migraine headache. 30-90% of migraine patients report such a phase . In the prodromal period, hours or days before the headache, some painless symptoms such as yawning, mood swings, difficulty concentrating, neck pain, fatigue, thirst, and increased frequency of urination may occur. . The prodromal period can last from hours to days. Aura may occur before the onset of a migraine headache. Often, the aura affects the patient's vision. Some patients with migraine may experience confusion, disorientation, tinnitus, dizziness and difficulty speaking, as well as seeing spots, flashes, and zigzags in their field of vision. These symptoms may occur 30 to 60 minutes before or during a migraine attack. Migraine pain can last for hours. During this time, the patient may want to rest in a quiet, dark environment and may have difficulty carrying out daily activities. Pain usually begins in the supraorbital region, particularly around the eyebrows, and then spreads to the unilateral temple region. Migraine has three phases. The prodrome phase is the period that includes the precursor symptoms that occur before the headache, accompanied by changes in the person's mood or cognitive functions, and sometimes accompanied by autonomic and systemic symptoms. If present, auras are monitored during this period. The pain phase includes the time when the headache occurs and ends after the prodromal period. Migraine postdrome phase is the period after the migraine attack until the headache symptoms disappear and return to normal. In the postdrome phase, patients usually report activity-limiting neuropsychiatric, sensory, and gastrointestinal symptoms and general malaise. During this period, the most common symptoms are neck stiffness, difficulty in concentration, and fatigue, while sensitivity to light, irritability, pallor, and nausea are also observed. Studies have shown that 68-81% of migraine patients have postdrome symptoms.
- Conditions
- Migraine, Pediatric Migraine
- Keywords
- Headache, migraine, pediatric, postdrome symptom
- Medical subject headings
- Migraine Disorders, Headache
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Pediatric Migraine Patients | Patients with non-migraine primary headaches, hemiplegic migraine, medication overuse, language or cognitive impairments, medical or psychiatric disorders, those older than 18 years of age, and those who were unwilling to participate in the study were exclude |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reporting post-migraine symptoms according to age and gender.
The aim of this study is to report clinical findings observed during the postdrome period (prodrome, aura, and headache) and at other times following childhood migraine attacks, according to gender and age.
Measured: Between 01.04.2021 and 01.09.2021
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 May 2026
- Study start1 Apr 2021
- Primary completion1 Sep 2021
- Study completion1 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MigraineStudies of the same condition, open and under way.
- More trials run by Mersin UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mersin University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aysen Orman, Balikesir University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07593287
- Sponsor's protocol ID
- Balikesir University Pediatric
- Status last verified
- May 2026
- First submitted
- 7 May 2026
- Last updated
- 18 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: special sensitive population
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- EVALUATİON OF POSTDROME FİNDİNGS İN PEDAİTRİC MİGRAİNE PATİENTS
- ClinicalTrials.gov ID
- NCT07593287
- Acronym / sponsor ID
- Balikesir University Pediatric
- Conditions
- Migraine, Pediatric Migraine
- Keywords
- Headache, migraine, pediatric, postdrome symptom
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 45 participants (actual)
- Lead sponsor
- Mersin UniversityUniversity, hospital or other
- Study start
- 1 Apr 2021 (actual)
- Primary completion
- 1 Sep 2021 (actual)
- Study completion
- 1 Dec 2021 (actual)
- First posted
- 18 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Migraine is a common neurological disease in the pediatric population. However, studies investigating the clinical symptoms associated with the different phases of migraine attacks (prodrome, aura, postdrome), particularly in childhood and adolescence, remain limited. The aim of this study was to evaluate the clinical symptoms experienced by children with migraine during attack phases (prodrome, aura, postdrome) and to investigate potential differences in these symptoms according to age and gender The first 18 questions assessed sociodemographic variables, including age, sex, body weight, parental characteristics, social status, age at migraine diagnosis and symptoms, knowledge of migraine, family history of migraine, comorbid conditions, and access to healthcare services. The second part of the questionnaire consisted of questions on headache and migraine-related symptoms and clinical characteristics (questions 19-26), migraine treatment (questions 28-34), and postdrome features (questions 35-39). The study examined migraine-related symptoms and clinical characteristics, treatment approaches, and the influence of sex and age group on the stages of migraine.
All patients underwent an assessment of headaches within the last three months, along with physical and neurological examinations. The diagnosis of migraine was made according to the ICHD-III criteria.
Detailed description
A migraine attack consists of four main stages. These stages are premonitory, aura, headache and postdrome periods. The prodromal or premonitory phase of migraine is generally defined as the period 2-48 hours before the aura or migraine headache. 30-90% of migraine patients report such a phase . In the prodromal period, hours or days before the headache, some painless symptoms such as yawning, mood swings, difficulty concentrating, neck pain, fatigue, thirst, and increased frequency of urination may occur. . The prodromal period can last from hours to days. Aura may occur before the onset of a migraine headache. Often, the aura affects the patient's vision. Some patients with migraine may experience confusion, disorientation, tinnitus, dizziness and difficulty speaking, as well as seeing spots, flashes, and zigzags in their field of vision. These symptoms may occur 30 to 60 minutes before or during a migraine attack. Migraine pain can last for hours. During this time, the patient may want to rest in a quiet, dark environment and may have difficulty carrying out daily activities. Pain usually begins in the supraorbital region, particularly around the eyebrows, and then spreads to the unilateral temple region. Migraine has three phases. The prodrome phase is the period that includes the precursor symptoms that occur before the headache, accompanied by changes in the person's mood or cognitive functions, and sometimes accompanied by autonomic and systemic symptoms. If present, auras are monitored during this period. The pain phase includes the time when the headache occurs and ends after the prodromal period. Migraine postdrome phase is the period after the migraine attack until the headache symptoms disappear and return to normal. In the postdrome phase, patients usually report activity-limiting neuropsychiatric, sensory, and gastrointestinal symptoms and general malaise. During this period, the most common symptoms are neck stiffness, difficulty in concentration, and fatigue, while sensitivity to light, irritability, pallor, and nausea are also observed. Studies have shown that 68-81% of migraine patients have postdrome symptoms.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pediatric Migraine Patients | – | –Patients with non-migraine primary headaches, hemiplegic migraine, medication overuse, language or cognitive impairments, medical or psychiatric disorders, those older than 18 years of age, and those who were unwilling to participate in the study were exclude |
Who may qualify
- Ages
- 6 to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- Pediatric migraine
Key inclusion criteria (0 listed)
Key exclusion criteria (4 listed)
- Primary headaches
- Hemiplegic migraine
- Depression
- Anxiety
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Reporting post-migraine symptoms according to age and gender.
Time frame: Between 01.04.2021 and 01.09.2021
The aim of this study is to report clinical findings observed during the postdrome period (prodrome, aura, and headache) and at other times following childhood migraine attacks, according to gender and age.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2026.
- Individual participant dataSharing planned: No. special sensitive population
Related trials for Migraine
RecruitingObservational study
Study of the Glymphatic System in Migraine
Migraine
Active, not recruiting
Clinical and Neurophysiological Effects of tDCS to Visual and Motor Cortex in Migraine
Migraine
Active, not recruiting
App-Based Migraine Treatment: The Health enSuite Study
Migraine, Migraine With Aura
Not yet recruiting
A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals
Migraine Disorders
Recruiting
Marine Lipids Ease Painful TMD
Temporomandibular Disorder (TMD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Migraine and Pediatric Migraine, run by Mersin University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reporting post-migraine symptoms according to age and gender. (time frame: Between 01.04.2021 and 01.09.2021). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2026.